Effects of Ras homolog gene family, member C gene silencing combined with rapamycin on hepatocellular carcinoma cell growth

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5077-5085

  Xie, Shu Li ^a   Zhu, Ming Guang ^b   Chen, Guo Fu ^a   Wang, Guang Yi ^a   Lv, Guo Yue ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Gene silencing; Hepatocellular carcinoma; Member C; Phosphoinositide 3 kinase AKT mammalian target of rapamycin; Rapamycin; Ras homolog gene family

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GELATINASE A; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; RHO KINASE; SILVER NITRATE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; P16 PROTEIN, HUMAN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; ONCOGENE; PROTEIN EXPRESSION; RHOC GENE; RNA INTERFERENCE; SOFT AGAR CLONOGENIC ASSAY; STAINING; WESTERN BLOTTING; WRIGHT STAINING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CYTOLOGY; DIFFUSION CHAMBER; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; DIFFUSION CHAMBERS, CULTURE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEPATOCYTES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RHO GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940568225     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4056     Document Type: Article

References (27)

1. Abdel-Rahman O: Systemic therapy for hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl Canc Inst 25: 165-171, 2013.
2. Harrold JM, Ramanathan M and Mager DE: Network-based approaches in drug discovery and early development. Clin Pharmacol Ther 94: 651-658, 2013.
3. Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ and Niu ZF: The role of RhoC in ovarian epithelial carcinoma: A marker for carci-nogenesis, progression, prognosis and target therapy. Gynecol Oncol 130: 570-578, 2013.
4. Islam M, Sharma S, Kumar B and Teknos TN: Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 49: 778-786, 2013.
5. Wu Y, Chen YC, Sang JR and Xu WR: RhoC protein stimulates migration of gastric cancer cells through interaction with scaffold protein IQGAP1. Mol Med Rep 4: 697-703, 2011.
6. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ and Liu HL: Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90: 2349-2355, 2004.
7. Xie S, Zhu M, Lv G, Zhang Q and Wang G: The role of RhoC in the proliferation and apoptosis of hepatocellular carcinoma cells. Med Oncol 29: 1802-1809, 2012.
8. Xie S, Zhu M, Lv G, Geng Y, Chen G, Ma J and Wang G: Overexpression of Ras homologous C (RhoC) induces malignant transformation of hepatocytes in vitro and in nude mouse xeno-grafts. PLoS One 8: e54493, 2013.
9. Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther 12: 1347-1357, 2012.
10. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ and Pavletich NP: mTOR kinase structure, mechanism and regulation. Nature 497: 217-223, 2013.
11. Diaz-Padilla I, Duran I, Clarke BA and Oza AM: Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 38: 767-775, 2012.
12. Sendur MA, Aksoy S, Zengin N and Altundag K: Comparative effcacy study of 5-year letrozole or anastrozole in postmeno-pausal hormone receptor-positive early breast cancer. J BUON 18: 838-844, 2013.
13. Khan KH, Yap TA, Yan L and Cunningham D: Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32: 253-265, 2013.
14. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, Winkler S, Houben P, Schultze D, Hatano E, et al: Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma-systematic review and meta-analysis. Cancer Med 2: 862-871, 2013.
15. Finn RS: Current and future treatment strategies for patients with advanced hepatocellular carcinoma: Role of mtor inhibition. Liver Cancer 1: 247-256, 2012.
16. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA and Shellman YG: RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126: 862-868, 2006.
17. Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY and van Golen KL: Regulation of infammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase. Mol Cancer Res 10: 1306-1318, 2012.
18. Jin Z: Experimental research on the combined effects of RhoC-siRNA and rapamycin in hepatocellular carcinoma cell line. Master Thesis of Jilin University 34-36, 2010.
19. Grise F, Bidaud A and Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795: 137-151, 2009.
20. Wilson KF, Erickson J W, Antonyak MA and Cerione RA: Rho GTPases and their roles in cancer metabolism. Trends Mol Med 19: 74-82, 2013.
21. Karlsson R, Pedersen ED, Wang Z and Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys Acta 1796: 91-98, 2009.
22. Populo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 13: 1886-1918, 2012.
23. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M: Targeting cell cycle regulation in cancer therapy. Pharmacol Ther 138: 255-271, 2013.
24. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29: 2513-2517, 2009.
25. Wu MH, Lo JF, Kuo CH, Lin JA, Lin YM, Chen LM, Tsai FJ, Tsai CH, Huang CY and Tang CH: Endothelin-1 promotes MMP-13 production and migration in human chondro-sarcoma cells through FAK/PI3K/Akt/mTOR pathways. J Cell Physiol 227: 3016-3026, 2012.
26. Chaudhary AK, Pandya S, Ghosh K and Nadkarni A: Matrix metalloproteinase and its drug targets therapy in solid and hema-tological malignancies: An overview. Mutat Res 753: 7-23, 2013.
27. Liu Z, Cheng M and Cao M: Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma. Biomed Imaging Interv J 7: e5, 2011.